

methylation assays on selective mDNMT1 mutants appear to support structure-based molecular insights into substrate recognition by DNMT1.

Maintenance of DNA methylation patterns during cell division is crucial to animal development. DNMT1 is tethered to the DNA replication fork and is the major player in maintaining DNA methylation patterns during replication. The current structure of the productive mDNMT1-DNA complex, when combined with our earlier structure of the corresponding autoinhibited complex (12), establishes that two distinct but mutually supportive mechanisms are used by DNMT1 to ensure faithful maintenance of DNA methylation patterns after replication. As unmethylated CpG dinucleotides emerge from the replication complex, such sites are protected from de novo methylation by the autoinhibitory mechanism. On the other hand, as hemimethylated CpG sites emerge from the replication complex, specific recognition by the TRD domain of DNMT1 makes such sites optimal targets for maintenance DNA methyl-

ation. These two mechanisms, working in tandem and mutually supportive of each other, together with anticipated regulation by other proteins in the replication complex (such as UHRF1), ensure the fidelity of DNMT1-mediated maintenance DNA methylation.

References and Notes

1. X. Cheng, R. M. Blumenthal, *Structure* **16**, 341 (2008).
2. M. G. Goll, T. H. Bestor, *Annu. Rev. Biochem.* **74**, 481 (2005).
3. J. A. Law, S. E. Jacobsen, *Nat. Rev. Genet.* **11**, 204 (2010).
4. M. M. Suzuki, A. Bird, *Nat. Rev. Genet.* **9**, 465 (2008).
5. E. Li, T. H. Bestor, R. Jaenisch, *Cell* **69**, 915 (1992).
6. L. S. Chuang *et al.*, *Science* **277**, 1996 (1997).
7. M. R. Rountree, K. E. Bachman, S. B. Baylin, *Nat. Genet.* **25**, 269 (2000).
8. H. Leonhardt, A. W. Page, H. U. Weier, T. H. Bestor, *Cell* **71**, 865 (1992).
9. J. H. Lee, K. S. Voo, D. G. Skolnik, *J. Biol. Chem.* **276**, 44669 (2001).
10. M. Pradhan *et al.*, *Biochemistry* **47**, 10000 (2008).
11. I. Callebaut, J. C. Courvalin, J. P. Morron, *FEBS Lett.* **446**, 189 (1999).
12. J. Song, O. Rechtkoblit, T. H. Bestor, D. J. Patel, *Science* **331**, 1036 (2011).

13. D. G. Osterman, G. D. DePillis, J. C. Wu, A. Matsuda, D. V. Santi, *Biochemistry* **27**, 5204 (1988).
14. S. Klimasauskas, S. Kumar, R. J. Roberts, X. Cheng, *Cell* **76**, 357 (1994).
15. K. M. Reinisch, L. Chen, G. L. Verdine, W. N. Lipscomb, *Cell* **82**, 143 (1995).
16. K. Takeshita *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **108**, 9055 (2011).

Acknowledgments: Supported by funds from the Abby Rockefeller Mauze Trust and STARR and Maloris Foundations (D.J.P.). We thank T. Bestor and M. Goll for helpful discussions, and the staff of the NE-CAT beamlines at the Advanced Photon Source, Argonne National Laboratory, for access and assistance with data collection. The structure of the complex has been deposited under accession no. 4DA4 in the Protein Data Bank.

Supporting Online Material

www.sciencemag.org/cgi/content/full/335/6069/709/DC1
Materials and Methods
Figs. S1 to S17
Tables S1 and S2
References (17–21)

26 September 2011; accepted 12 January 2012
10.1126/science.1214453

Structure and Allostery of the PKA RII β Tetrameric Holoenzyme

Ping Zhang,¹ Eric V. Smith-Nguyen,² Malik M. Keshwani,^{1,3} Michael S. Deal,² Alexandr P. Kornev,^{2,3} Susan S. Taylor^{1,2,3*}

In its physiological state, cyclic adenosine monophosphate (cAMP)–dependent protein kinase (PKA) is a tetramer that contains a regulatory (R) subunit dimer and two catalytic (C) subunits. We describe here the 2.3 angstrom structure of full-length tetrameric RII β :C $_2$ holoenzyme. This structure showing a dimer of dimers provides a mechanistic understanding of allosteric activation by cAMP. The heterodimers are anchored together by an interface created by the β 4– β 5 loop in the RII β subunit, which docks onto the carboxyl-terminal tail of the adjacent C subunit, thereby forcing the C subunit into a fully closed conformation in the absence of nucleotide. Diffusion of magnesium adenosine triphosphate (ATP) into these crystals trapped not ATP, but the reaction products, adenosine diphosphate and the phosphorylated RII β subunit. This complex has implications for the dissociation-reassociation cycling of PKA. The quaternary structure of the RII β tetramer differs appreciably from our model of the RI α tetramer, confirming the small-angle x-ray scattering prediction that the structures of each PKA tetramer are different.

Cyclic adenosine monophosphate (cAMP)–dependent protein kinase (PKA), a ubiquitous serine/threonine protein kinase, exists in mammalian cells as an inactive tetrameric holoenzyme composed of a regulatory (R) subunit dimer and two catalytic (C) subunits. cAMP binding to the R subunits releases the active C subunits, allowing them to phosphorylate specific substrate proteins. The two classes of R subunit, RI and RII, each have α and β isoforms, and

these functionally nonredundant isoforms are a primary mechanism for achieving specificity in PKA signaling (1). Deletion of RI α , for example, is embryonically lethal (2), whereas RII β knockout mice have a lean phenotype and are not susceptible to diet-induced insulin resistance (3, 4). Depletion of RII β reverses the obesity syndrome of agouti mice (5). RII β is the predominant isoform in brain and adipose tissue (2, 6). RII subunits are typically anchored to membrane proteins through high-affinity binding to adenosine kinase-anchoring proteins (AKAPs).

The crystal structure of the C subunit revealed the conserved kinase core shared by all members of the protein kinase superfamily (7, 8). It is bilobal with a large, helical C lobe (Fig. 1A) that facilitates substrate recognition and provides the catalytic machinery for phosphoryl transfer and a smaller, more dynamic beta-rich N lobe that is

associated mostly with adenosine triphosphate (ATP) binding (7, 9, 10). The C-terminal tail (C tail), a conserved feature of kinases belonging to the AGC subfamily, serves as a cis-regulatory element that wraps around both lobes and primes the C subunit for catalysis (11).

Each R subunit (Fig. 1A) contains an N-terminal dimerization/docking (D/D) domain, followed by a flexible linker containing an inhibitor site (IS) that docks to the active-site cleft of the C subunit in the holoenzyme. At the C terminus are two tandem highly conserved cyclic nucleotide-binding domains (CNB-A and CNB-B) (12). PKA is anchored to specific sites in the cell by binding of an AKAP amphipathic helix to the D/D domain (13, 14). RII ISs have a Ser at their phosphorylation site (P site) and are both substrates and inhibitors, whereas RI subunits with Gly or Ala at their P site are inhibitors and pseudosubstrates. Phosphorylation of the P-site Ser in RII slows the rate of association with C subunit (15, 16), and formation of holoenzyme in cells is influenced substantially depending on whether the P-site residue is a substrate or a pseudosubstrate (12, 17). In contrast to RII subunits, forming a high-affinity type I holoenzyme with RI subunits requires Mg $_2$ ATP (18).

Complexes of R and C subunits, first described with truncated monomeric R subunits, showed for the first time how the C subunit was inhibited by R and how the complex was activated by cAMP (19–22). These RI α , RII α , and RII β heterodimeric complexes also showed that the R subunits undergo a dramatic conformational change as they release cAMP and bind to C subunit. However, in the absence of cAMP, PKA in cells exists as a tetramer, and only a full-length tetrameric holoenzyme structure will explain how PKA is assembled in its physiological state and how it acquires its allosteric properties. A model of the (RI α) $_2$:C $_2$ holoenzyme was proposed recently (23),

¹Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA 92093–0654, USA. ²Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093–0654, USA. ³Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093–0654, USA.

*To whom correspondence should be addressed. E-mail: staylor@ucsd.edu

but so far there is no full-length tetrameric structure of PKA. Furthermore, although different PKA holoenzyme isoforms have similar domain organizations, each holoenzyme, based on small-angle x-ray scattering (SAXS), has a different quaternary structure (24, 25); perhaps most notable is the difference between RII α and RII β holoenzymes (24). SAXS showed that both RII homodimers are elongated; however, RII β holoenzyme becomes compact, whereas RII α holoenzyme remains extended. To understand the structural and functional nonredundancy of the PKA isoforms requires structures of tetrameric holoenzymes.

To crystallize a tetrameric RII β :C $_2$ holoenzyme, we generated wild-type RII β (1-416), and, in an effort to stabilize the holoenzyme, we also

expressed and purified two mutants that abolished high-affinity binding of cAMP in CNB-A [RII β (R230K)] and CNB-B [RII β (R359K)], respectively. Only the RII β (R230K) holoenzyme produced well-diffracting crystals. The crystal structure of the tetrameric RII β (R230K) $_2$:C $_2$ holoenzyme (labeled as RII β * $_2$:C $_2$) was solved at 2.3 Å (Fig. 1, fig. S1, and table S1). Although residues 1 to 103, 122 to 129, and 394 to 416 of RII β and residues 1 to 13 of C are missing in the electron density, we validated by using gel electrophoresis that the full-length RII β :C $_2$ complex is in the protein crystal. The absence of density for the N-terminal D/D domain and the following linker is likely related to the flexible nature of this region.

The structure confirms the SAXS predictions (24) that the highly extended RII β dimer folded up into a compact holoenzyme (fig. S2). The compact, doughnut-shaped tetramer contains two R:C heterodimers (labeled RC and R'C') with a rotational twofold symmetry through the central cavity (Fig. 1, B and C). This structure also reveals the dramatic changes that take place in the RII β subunit as it releases cAMP and binds to C subunit (Fig. 1D). In the cAMP-bound state, two hydrophobic capping residues (Arg^{381R} for CNB-A and Tyr^{397R} for CNB-B) are bound to the adenine rings of cAMP (26, 27). These two residues move away from the cAMP binding sites in the holoenzyme (38 Å for Arg^{381R}) and are kept in this distal location by a holoenzyme-specific salt bridge between Arg^{392R} and Glu^{282R} (Fig. 1D). This salt bridge is important for allosteric activation (20, 22) and is conserved in all R-subunit isoforms (12).

The C subunits are well separated, whereas each R subunit contacts the neighboring R:C heterodimers by using the highly conserved but isoform-specific β 4- β 5 loop in the CNB-A domain (fig. S3). This loop is exposed to solvent in the free cAMP-bound R subunit (Fig. 1D) and also in the heterodimer (20, 22); however, in the tetramer it reaches over to the opposite dimer and creates an extensive interface. The area of each interface between the two heterodimers, which are strictly twofold rotational symmetry related, is \sim 500 Å². The major site of contact is to the C-terminal tail of the opposite C subunit, specifically the active-site tether (AST, residues 320 to 339) segment. The C tail (residues 301 to 350 in PKA) is a highly conserved feature of all AGC kinases (11). Residues 301 to 318, referred to as the C-lobe tether, are anchored firmly to the C lobe, whereas residues 336 to 350, referred to as the N-lobe tether, are anchored through a hydrophobic motif to the N lobe. The intervening AST segment, typically disordered in the absence of nucleotide, becomes an integral part of the ATP binding site when nucleotide is bound. A conserved Phe-Asp-Tyr (FDDY) motif (residues 327 to 330) in this region, in particular Phe^{327C} and Tyr^{330C}, are part of the hydrophobic pocket that anchors the adenine and ribose rings of ATP. When either residue is replaced with Ala, enzymatic activity is lost and affinity for ATP is reduced (28, 29). In the holoenzyme, the β 4- β 5 loop docks to the back of the FDDY motif, pushing it and the entire N lobe into a fully closed conformation even though the nucleotide is absent. The β 4- β 5 loop also interacts with a portion of the R-subunit N linker from the opposite heterodimer. The details of these interactions are described in fig. S3.

Ordering of the C tail and the N lobe by the β 4- β 5 loop into a closed conformation independent of ATP is one of the most striking features of the RII β tetrameric holoenzyme and distinguishes it from the heterodimer and from all previous structures of the C subunit, which are only in a closed conformation when ATP and two magnesium ions are bound (Fig. 2A). In this structure,




Fig. 1. Overall view of the RII β * $_2$:C $_2$ tetrameric holoenzyme. **(A)** Domain organization and color coding of the R and C subunits. The four red spheres indicate the phosphorylation sites in C subunit. **(B)** Structure of the RII β * $_2$:C $_2$ tetrameric holoenzyme. The N lobe of the C subunit is white; the C lobe and C tail are tan. The N-linker segment of the R subunit that contains the IS and docks to the active-site cleft of the C subunit is shown as a red ribbon. One heterodimer is labeled RC, and its twofold symmetry mate is labeled as R'C'. The twofold axis position is shown as a black oval (left) and dotted line (right). **(C)** One RII β :C heterodimeric holoenzyme structure in the RII β * $_2$:C $_2$ tetrameric holoenzyme. **(D)** RII β undergoes dramatic conformational changes upon binding to the C subunit. RII β bound to the C subunit is shown on the left and bound to cAMP shown on the right (PDB ID code 1CX4, in black). The salt bridge Glu^{282R}-Arg^{392R} formed upon binding to the C subunit is shown in an orange circle.

Ser^{53C} at the tip of the Gly-rich loop interacts with the backbone carbonyl of the P-site Ser^{112R}, and this is a hallmark of the closed conformation. Ser^{112R} also forms hydrogen bonds with catalytic loop residues Asp^{166C} and Lys^{168C} (Fig. 2A). In the RI α heterodimer, the C subunit is also in a closed conformation that requires Mg₂ATP, whereas in the RI β heterodimer, where high-affinity binding does not require Mg₂ATP (18), the C subunit is in an open conformation with an empty ATP binding pocket and a disordered C tail (Fig. 2B) (20, 22). Comparing temperature factors (B factor) of C subunits in different R:C complexes reveals regions of relative order and disorder (Fig. 2B and table S2). The nucleotide-bound RI α (91-379):C heterodimer is in a fully closed conformation and has low B-factors both in the N and C lobe (Fig. 2B and table S2). In contrast, the nucleotide-free RI β (90-400):C dimer has high B factors in the N lobe, and the C tail is partially disordered, consistent with its open conformation (Fig. 2B). The apo nucleotide-free tetrameric holoenzyme, similar to the nucleotide-bound RI α complex, has low B factors in both lobes, which reflects its closed conformation and ordered C tail (Fig. 2B).

The allosteric properties of the RI β holoenzyme are also different from the RI β heterodimer and from the other three PKA isoforms. The activation constant (K_a) for activation of the RI β tetramer by cAMP is 584 nM, and this is significantly higher than the K_a for other holoenzymes [101 nM for RI α (30), 29 nM for RI β (31), and 137 nM for RI α (Fig. 4A)]. It is also higher than the K_a of 65nM for RI β heterodimer (Fig. 3). The increased K_a for the RI β tetrameric holoenzyme can be explained by the extensive interfaces between the two heterodimers, where the phosphate-binding cassette (PBC) docking site for cAMP in CNB-A is juxtapositioned directly against the ATP binding site in N lobe of the C subunit in the opposite heterodimer (Fig. 3B). The Hill coefficient for the RI β tetramer is 1.7, in contrast to 0.65 for the heterodimers, which indicates that allostery is unique to the tetramer. The considerable cross-talk between the two CNB domains and the between the two heterodimers is also reflected by several mutations. When the CNB-B domain is deleted entirely, for example, the K_a for activation is 60 nM and the Hill coefficient is reduced to 1.2, indicating that there is still substantial allosteric cross-talk between the two CNB-A domains (31, 32) (Fig. 3C). When the cAMP binding site in the CNB-A domain is deleted, the K_a for activation is very high, 13 μ M, confirming that cAMP binding to CNB-A is essential for activation. However, when the B domain is mutated, the enzyme still has a similar K_a for activation (490 nM), but all cooperativity is lost. The molecular basis for this complex allostery could simply not be appreciated in the absence of the holoenzyme structure.

Given that the ATP binding chamber in the C subunit is perfectly formed and locked into a closed conformation, we hypothesized that ATP could diffuse into this pocket without breaking




Fig. 2. C subunit is in a closed conformation. **(A)** The active site of the C subunit in the RI β *₂:C₂ tetrameric holoenzyme is fully closed in the absence of ATP. S, Ser; K, Lys. **(B)** The conformation and B factors analysis of the C subunit in three holoenzyme structures. The left bottom is the scale bar for B factors.




Fig. 3. Allosteric cAMP activation mechanism for the RI β holoenzyme. **(A)** Overall interactions of the RC and R'C'. The two symmetry-related interfaces are shown in orange circles. **(B)** The binding site for cAMP to CNB-A' in R'C' heterodimer (left arrow) is juxtapositioned directly against the ATP binding site (right arrow) in the N lobe of the C subunit in the symmetry-related RC dimer. **(C)** Activation of holoenzymes by cAMP. The K_a values for activation were measured as a function of cAMP. Each holoenzyme is designated as follows: RI α (90-400):C(□), RI β (108-402):C(▽), RI α *₂:C₂(■), WT RI β *₂:C₂(▼), and RI β *₂:C₂(◇).

the crystal lattice. We thus soaked the apo crystals with MgATP (materials and methods). The resulting crystals, solved to a resolution of 3.1 Å (table S1), showed that nucleotide had diffused into the active site. However, instead of finding ATP, we found the reaction products, Mg₂ADP and the phosphorylated RIIβ subunit (Fig. 4 and fig. S5). This is the first time that we have trapped both reaction products in the active-site cleft, and such a complex has also not been observed for other protein kinases. Even trapping a transition state complex has been challenging, and PKA is one of the few examples where this has been possible (33). The overall RIIβ^P₂:C₂:(Mg₂ADP)₂ structure closely resembles the apo RIIβ^P₂:C₂ structure (fig. S5) with a Ca root mean square deviation (RMSD) of 0.67 Å. The C subunit still remains in

a closed conformation and still has low B factors in both the C and N lobe (table S2). The B factors in the phosphorylated inhibitor site of RIIβ are also low. There is an ~5 Å shift of the tip residue Ser^{53C} in the Gly-rich loop from its position in the apo structure, which is sufficient to break the hydrogen bond between the Ser^{53C} and Ser^{112R} (Fig. 2A and fig. S5). Thus, the RIIβ^P₂:C₂:(Mg₂ADP)₂ tetramer contains a perfectly formed stable reaction chamber that allows for catalysis, but the reaction products were trapped. We hypothesize that this complex may be a physiologically relevant state for the RIIβ holoenzyme.

Typically the RIIβ₂:C₂ holoenzyme is colocalized through AKAPs with protein phosphatases (PPs) (34). For example, calcineurin, a calcium-activated phosphatase, and PKA RII holoenzymes

are colocalized at the C terminus of AKAP79/150 (34). Because the RII inhibitor sites are excellent substrates for calcineurin, it has been assumed that the RIIβ subunit is dephosphorylated by calcineurin to facilitate its reassociation with C subunits (15, 16). However, a recent report suggests that the RII subunits in cardiac myocytes are mostly phosphorylated in the absence of forskolin (35). Although this observation needs to be further validated, our structure suggests that in cells the inactive RIIβ₂:C₂ holoenzyme, once formed, may be primed to have its R subunits autophosphorylated (Fig. 4C) given the high availability of cytoplasmic MgATP. This presents the following scenario. Cooperative CAMP activation leads to dissociation of the C subunits from the RIIβ^P homodimer. Nearby phosphatases like calcineurin, localized in close proximity to the RII holoenzyme (34, 36), can then modulate PKA activity by dephosphorylating the RIIβ^P subunit when calcium levels are elevated, thereby facilitating the regeneration of inactive RIIβ₂:C₂ holoenzyme (15, 16). This apo RIIβ₂:C₂ holoenzyme can then get autophosphorylated with cytoplasmic MgATP yet stay in an inactive form (Fig. 4C) until cAMP levels are elevated again.

Anchoring of RII holoenzymes near membranes is mediated by the D/D domain binding to AKAPs, and, from the position of the traced N linker of the two RIIβ chains (fig. S6) and the available space in crystal packing, the position of the missing D/D domain can be predicted. In our RIIβ structure, the first 13 residues of the C subunit are disordered, whereas in the free C subunit the myristyl group is folded into a hydrophobic pocket in the C lobe of the C subunit (37). Fluorescence anisotropy studies showed that binding of the RIIβ subunit causes the myristylated N tail to become more flexible and dynamic, and, in contrast to free C and the RIα tetramer, the RII holoenzyme interacts with membrane vesicles (38). When the RIIβ holoenzyme is targeted by AKAPs to membrane proteins, the exposed myristyl groups will likely be on the same surface as the AKAP, which provides an opportunity for multivalent membrane anchoring. The holoenzyme targeted to membranes also has the potential to interact with other signaling proteins, such as adenylate cyclases (ACs), heterotrimeric guanine nucleotide-binding (G) proteins, G protein-coupled receptors (GPCRs), and phosphodiesterases (PDEs) in addition to AKAPs, and thus could contribute to the assembly of larger macromolecular complexes. These interactions would create enormous opportunities for synergy that now need to be considered more rigorously.

A comparison of our model of the RIα tetrameric holoenzyme (23) with the RIIβ holoenzyme (Fig. 5 and fig. S7) shows how isoform-specific quaternary structures can be created even though the tertiary structures of the heterodimers are remarkably similar for RIα, RIα (20, 22), and RIIβ. By forming a dimer of dimers, a twofold axis of symmetry is created in the tetrameric holoenzyme; however, the specific interface between




Fig. 4. RIIβ^P₂:C₂:(Mg₂ADP)₂ tetrameric holoenzyme. (A) Two Mg²⁺ ions coordinate interactions in the active site of RIIβ^P₂:C₂:(Mg₂ADP)₂. MgI coordinates the β phosphate of ADP, the transferred γ phosphate, and residue Asp^{184C} in the DFG loop; whereas MgII coordinates both α and β phosphates of ADP, the transferred γ phosphate, and residues Asp^{184C} and Asn (N)^{171C}. (B) Electron density map of ATP hydrolyzed to ADP and γ phosphate transferred to P-site Ser^{112R}. (C) Schematic model of autophosphorylation of RIIβ in cells.




Fig. 5. Comparison of RIα₂:C₂ model (3PVB) and RIIβ₂:C₂ structure. Although each holoenzyme creates a twofold symmetry, the interface is completely different in the two tetramers. The N-linker is red and β4-β5 loop is green. The axes of symmetry are also indicated by the black ovals.

the dimers is different for each R-subunit isoform. In each case, however, the $\beta 4$ - $\beta 5$ loop in the R subunit appears to serve a specificity determinant for docking between the two heterodimers. By comparing the RII β tetramer with a model of the RI α holoenzyme, we see how distinct quaternary architectures can be created. It is only by comparing the full-length holoenzymes that we can appreciate that the functional nonredundancy of the PKA isoforms is also reflected in the structural nonredundancy of these isoforms. Correlating these structural differences with functional consequences will be our next challenge.

References and Notes

1. P. S. Amieux *et al.*, *J. Biol. Chem.* **277**, 27294 (2002).
2. P. S. Amieux *et al.*, *J. Biol. Chem.* **272**, 3993 (1997).
3. D. E. Cummings *et al.*, *Nature* **382**, 622 (1996).
4. S. A. Schreyer, D. E. Cummings, G. S. McKnight, R. C. LeBoeuf, *Diabetes* **50**, 2555 (2001).
5. T. A. Czyzyk, M. A. Sikorski, L. Yang, G. S. McKnight, *Proc. Natl. Acad. Sci. U.S.A.* **105**, 276 (2008).
6. G. McConnachie, L. K. Langeberg, J. D. Scott, *Trends Mol. Med.* **12**, 317 (2006).
7. D. R. Knighton *et al.*, *Science* **253**, 407 (1991).
8. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, *Science* **298**, 1912 (2002).
9. X. Cheng, C. Phelps, S. S. Taylor, *J. Biol. Chem.* **276**, 4102 (2001).
10. D. A. Johnson, P. Akamine, E. Radzio-Andzelm, M. Madhusudan, S. S. Taylor, *Chem. Rev.* **101**, 2243 (2001).
11. N. Kannan, N. Haste, S. S. Taylor, A. F. Neuwald, *Proc. Natl. Acad. Sci. U.S.A.* **104**, 1272 (2007).
12. J. M. Canaves, S. S. Taylor, *J. Mol. Evol.* **54**, 17 (2002).
13. F. S. Kinderman *et al.*, *Mol. Cell* **24**, 397 (2006).
14. M. G. Newlon *et al.*, *EMBO J.* **20**, 1651 (2001).
15. M. Diskar, H. M. Zenn, A. Kaupisch, A. Prinz, F. W. Herberg, *Cell. Signal.* **19**, 2024 (2007).
16. R. Rangel-Aldao, O. M. Rosen, *J. Biol. Chem.* **251**, 3375 (1976).
17. B. R. Martin, T. J. Deerinck, M. H. Ellisman, S. S. Taylor, R. Y. Tsien, *Chem. Biol.* **14**, 1031 (2007).
18. F. W. Herberg, S. S. Taylor, *Biochemistry* **32**, 14015 (1993).
19. S. H. Brown, J. Wu, C. Kim, K. Alberto, S. S. Taylor, *J. Mol. Biol.* **393**, 1070 (2009).
20. C. Kim, C. Y. Cheng, S. A. Saldanha, S. S. Taylor, *Cell* **130**, 1032 (2007).
21. C. Kim, N.-H. Xuong, S. S. Taylor, *Science* **307**, 690 (2005).
22. J. Wu, S. H. J. Brown, S. von Daake, S. S. Taylor, *Science* **318**, 274 (2007).
23. A. J. Boettcher *et al.*, *Structure* **19**, 265 (2011).
24. D. Vigil, D. K. Blumenthal, S. S. Taylor, J. Trehwella, *J. Mol. Biol.* **357**, 880 (2006).
25. W. T. Heller *et al.*, *J. Biol. Chem.* **279**, 19084 (2004).
26. H. M. Berman *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **102**, 45 (2005).
27. T. C. Diller, N. H. Xuong, S. S. Taylor, *Protein Expr. Purif.* **20**, 357 (2000).
28. M. Batkin, I. Schwartz, S. Shaltiel, *Biochemistry* **39**, 5366 (2000).
29. J. Yang *et al.*, *J. Biol. Chem.* **284**, 6241 (2009).
30. F. W. Herberg, S. S. Taylor, W. R. Dostmann, *Biochemistry* **35**, 2934 (1996).
31. G. G. Cadd, M. D. Uhler, G. S. McKnight, *J. Biol. Chem.* **265**, 19502 (1990).
32. K. M. Zawadzki, S. S. Taylor, *J. Biol. Chem.* **279**, 7029 (2004).
33. P. Madhusudan, N. H. Akamine, S. S. Xuong, Taylor, *Nat. Struct. Biol.* **9**, 273 (2002).
34. S. F. Oliveria, M. L. Dell'Acqua, W. A. Sather, *Neuron* **55**, 261 (2007).
35. S. Manni, J. H. Mauban, C. W. Ward, M. Bond, *J. Biol. Chem.* **283**, 24145 (2008).
36. D. D. Hall *et al.*, *Biochemistry* **46**, 1635 (2007).
37. J. Zheng *et al.*, *Protein Sci.* **2**, 1559 (1993).
38. M. Gangal *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **96**, 12394 (1999).

Acknowledgments: We thank members of the Taylor laboratory for helpful discussions and the Advanced Light Source (beam line 8.2.2) staff of Lawrence Berkeley National Laboratory for beam access and help with data collection. This work was supported by NIH grant GM34921 (S.S.T.). Coordinates and structure factors have been deposited in the Protein Data Bank (PDB) with accession numbers 3TNP and 3TNQ.

Supporting Online Material

www.sciencemag.org/cgi/content/full/335/6069/712/DC1
Materials and Methods
Figs. S1 to S7
Tables S1 and S2
References (39–42)

14 September 2011; accepted 3 January 2012
10.1126/science.1213979

The Crystal Structure of TAL Effector PthXo1 Bound to Its DNA Target

Amanda Nga-Sze Mak,^{1*} Philip Bradley,^{2*} Raul A. Cernadas,³
Adam J. Bogdanove,³ Barry L. Stoddard^{1†}

DNA recognition by TAL effectors is mediated by tandem repeats, each 33 to 35 residues in length, that specify nucleotides via unique repeat-variable diresidues (RVDs). The crystal structure of PthXo1 bound to its DNA target was determined by high-throughput computational structure prediction and validated by heavy-atom derivatization. Each repeat forms a left-handed, two-helix bundle that presents an RVD-containing loop to the DNA. The repeats self-associate to form a right-handed superhelix wrapped around the DNA major groove. The first RVD residue forms a stabilizing contact with the protein backbone, while the second makes a base-specific contact to the DNA sense strand. Two degenerate amino-terminal repeats also interact with the DNA. Containing several RVDs and noncanonical associations, the structure illustrates the basis of TAL effector–DNA recognition.

TAL effectors are proteins that are injected into plant cells by pathogens in the bacterial genus *Xanthomonas*. There they enter the nucleus, bind to effector-specific promoter sequences, and activate the expression of individual plant genes, which can either benefit the bacterium or trigger host defenses (1, 2). In each TAL effector, a variable number of tandem amino acid repeats (which are usually 34 residues in length), terminated by a truncated “half repeat,”

mediates DNA recognition. Each of the repeats preferentially associates with one of the four nucleotides in the target site (3, 4). The repeats are located centrally in the protein between N-terminal sequences required for bacterial type III secretion and C-terminal sequences required for nuclear localization and activation of transcription (Fig. 1A).

The nucleotide specificity of individual TAL effector repeats is encoded by two adjacent res-

idues (located at positions 12 and 13) called the repeat-variable diresidue (RVD) (Fig. 1, B and C) (4). More than 20 unique RVD sequences have been observed in TAL effectors, but just seven—HD, NG, NI, NN, NS, “N*” (which corresponds to a 33-residue repeat in which the RVD appears to be missing its second residue), and HG—account for nearly 90% of all repeats (5) and, respectively, specify C, T, A, G/A, A/C/T/G, C/T, and T (3, 4). These relationships enable prediction of targets for existing TAL effectors and engineering of artificial TAL effectors that bind DNA sequences of choice. Consequently, TAL effectors have received much attention as DNA-targeting tools (6).

Nearly all TAL effector binding sites observed in nature are preceded by a T (3, 4). Notably, the protein sequence immediately preceding the canonical TAL effector repeats bears some similarity to the repeat consensus. It has therefore been suggested that this region of the protein may participate in DNA binding by forming a cryptic repeat structure that specifies the T (7).

¹Division of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, A3-025 Seattle, WA 98019, USA. ²Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M1-B514 Seattle, WA 98109, USA. ³Department of Plant Pathology and Microbiology, Iowa State University, 351 Bessey Hall, Ames, IA 50011, USA.

*These authors contributed equally to this work.

†To whom correspondence should be addressed. E-mail: bstoddard@fhcr.org



Structure and Allostery of the PKA RII β Tetrameric Holoenzyme

Ping Zhang, Eric V. Smith-Nguyen, Malik M. Keshwani, Michael S. Deal, Alexandr P. Kornev and Susan S. Taylor (February 9, 2012)
Science **335** (6069), 712-716. [doi: 10.1126/science.1213979]

Editor's Summary

Keeping a Kinase in Check

Cyclic adenosine monophosphate (cAMP)–dependent protein kinase (PKA) is involved in the regulation of several key metabolic pathways. It exists in mammalian cells as an inactive tetramer composed of a regulatory (R) subunit dimer and two catalytic (C) subunits. cAMP binding causes activation by releasing the C subunits. Insight into PKA regulation has come from structures of R and C subunit heterodimers; however, further understanding requires knowledge of the holoenzyme structure. **P. Zhang *et al.*** (p. 712) report a high-resolution structure of the RII β ₂:C₂ tetramer. The structure reveals interactions at an interface between the two RC heterodimers and provides insight into the mechanism of allosteric activation upon cAMP binding.

This copy is for your personal, non-commercial use only.

Article Tools

Visit the online version of this article to access the personalization and article tools:

<http://science.sciencemag.org/content/335/6069/712>

Permissions

Obtain information about reproducing this article:

<http://www.sciencemag.org/about/permissions.dtl>

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.